Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx®), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study

Haematologica

Volumn 87, Issue 8, 2002, Pages 822-827

  Martino, Rodrigo ^a   Perea, Granada ^a   Caballero, María Dolores ^a   Mateos, María V ^a   Ribera, Josep M ^a   Pérez De Oteyza, Jaime ^a   Arranz, Reyes ^a   Terol, Maria José ^a   Sierra, Jorge ^a   San Miguel, Jesús F ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Caelyx , non Hodgkin's lymphoma; Elderly; Liposomal doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MACROGOL; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HAIR LOSS; HEART DISEASE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; REMISSION; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ERUPTION; MORTALITY; PROSPECTIVE STUDY; SURVIVAL;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMAN; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; NAUSEA; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMANS;

EID: 0035986759     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients
2. A predictive model for aggressive non-Hodgkin's lymphoma
3. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age
4. Initial chemotherapy for clinically localized lymphomas of unfavorable histology
5. Aggressive non-Hodgkin lymphoma in the elderly. A retrospective study of 72 patients with clinical features and treatment
6. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
7. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
8. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A groupe d' Etude des Lymphomes de l' Adulte study on 453 patients older than 69 years
9. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for research and treatment of Cancer Lymphoma Cooperative Study Group
10. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
11. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: Results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO
12. CEMP, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-Hodgkin's lymphoma: An effective and non toxic therapeutic alternative for adult and elderly patients
13. Continuous infusion of vincristine-doxorrubicin with bolus of dexamethasone (VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma
14. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: A prospective study
15. Phase II trials of liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
16. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
17. Intermediate and high grade non Hodgkin's lymphoma in the elderly
18. Doxorubicin-induced cardiomyopathy
19. Anthracyclines in haematology: Preclinical studies, toxicity and delivery sistems
20. Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer
21. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
22. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
23. Liposomal doxorubicin
24. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
25. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors
26. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
27. 2
28. Skin toxic effects of polyethylene glycolcoated liposomal doxorubicin
29. A safety review of pegylated liposomal doxorubicin in the treatment of various malignancies
30. First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkin's lymphoma (IGL) patients on standard-dose CHOP therapy
31. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
32. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
33. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
34. 2-weekly Chop (CHOP-14): The new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age